


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Clinical Medicine Notes">
      
      
        <link rel="canonical" href="https://jingzhian.github.io/mkdocs-md-notes/oncology/">
      
      
        <meta name="author" content="Jingzhi An">
      
      <link rel="shortcut icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.1, mkdocs-material-5.3.3">
    
    
      
        <title>Oncology - Clinical Medicine Notes</title>
      
    
    
      <link rel="stylesheet" href="../assets/stylesheets/main.fe0cca5b.min.css">
      
        <link rel="stylesheet" href="../assets/stylesheets/palette.a46bcfb3.min.css">
      
      
        
        
        <meta name="theme-color" content="#009688">
      
    
    
    
      
        <link href="https://fonts.gstatic.com" rel="preconnect" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,400,400i,700%7CRoboto+Mono&display=fallback">
        <style>body,input{font-family:"Roboto",-apple-system,BlinkMacSystemFont,Helvetica,Arial,sans-serif}code,kbd,pre{font-family:"Roboto Mono",SFMono-Regular,Consolas,Menlo,monospace}</style>
      
    
    
    
      <link rel="stylesheet" href="../stylesheets/numbered-headings.css">
    
    
      
    
    
  </head>
  
  
    
    
    
    <body dir="ltr" data-md-color-scheme="" data-md-color-primary="teal" data-md-color-accent="teal">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#oncology" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
      <header class="md-header" data-md-component="header">
  <nav class="md-header-nav md-grid" aria-label="Header">
    <a href="https://jingzhian.github.io/mkdocs-md-notes/" title="Clinical Medicine Notes" class="md-header-nav__button md-logo" aria-label="Clinical Medicine Notes">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 003-3 3 3 0 00-3-3 3 3 0 00-3 3 3 3 0 003 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54z"/></svg>

    </a>
    <label class="md-header-nav__button md-icon" for="__drawer">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2z"/></svg>
    </label>
    <div class="md-header-nav__title" data-md-component="header-title">
      
        <div class="md-header-nav__ellipsis">
          <span class="md-header-nav__topic md-ellipsis">
            Clinical Medicine Notes
          </span>
          <span class="md-header-nav__topic md-ellipsis">
            
              Oncology
            
          </span>
        </div>
      
    </div>
    
      <label class="md-header-nav__button md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0116 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 019.5 16 6.5 6.5 0 013 9.5 6.5 6.5 0 019.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5z"/></svg>
      </label>
      
<div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" data-md-state="active">
      <label class="md-search__icon md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0116 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 019.5 16 6.5 6.5 0 013 9.5 6.5 6.5 0 019.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5z"/></svg>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
      </label>
      <button type="reset" class="md-search__icon md-icon" aria-label="Clear" data-md-component="search-reset" tabindex="-1">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"/></svg>
      </button>
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header-nav__source">
        
<a href="https://github.com/jingzhian/mkdocs-md-notes/" title="Go to repository" class="md-source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path d="M400 32H48C21.5 32 0 53.5 0 80v352c0 26.5 21.5 48 48 48h352c26.5 0 48-21.5 48-48V80c0-26.5-21.5-48-48-48zM277.3 415.7c-8.4 1.5-11.5-3.7-11.5-8 0-5.4.2-33 .2-55.3 0-15.6-5.2-25.5-11.3-30.7 37-4.1 76-9.2 76-73.1 0-18.2-6.5-27.3-17.1-39 1.7-4.3 7.4-22-1.7-45-13.9-4.3-45.7 17.9-45.7 17.9-13.2-3.7-27.5-5.6-41.6-5.6-14.1 0-28.4 1.9-41.6 5.6 0 0-31.8-22.2-45.7-17.9-9.1 22.9-3.5 40.6-1.7 45-10.6 11.7-15.6 20.8-15.6 39 0 63.6 37.3 69 74.3 73.1-4.8 4.3-9.1 11.7-10.6 22.3-9.5 4.3-33.8 11.7-48.3-13.9-9.1-15.8-25.5-17.1-25.5-17.1-16.2-.2-1.1 10.2-1.1 10.2 10.8 5 18.4 24.2 18.4 24.2 9.7 29.7 56.1 19.7 56.1 19.7 0 13.9.2 36.5.2 40.6 0 4.3-3 9.5-11.5 8-66-22.1-112.2-84.9-112.2-158.3 0-91.8 70.2-161.5 162-161.5S388 165.6 388 257.4c.1 73.4-44.7 136.3-110.7 158.3zm-98.1-61.1c-1.9.4-3.7-.4-3.9-1.7-.2-1.5 1.1-2.8 3-3.2 1.9-.2 3.7.6 3.9 1.9.3 1.3-1 2.6-3 3zm-9.5-.9c0 1.3-1.5 2.4-3.5 2.4-2.2.2-3.7-.9-3.7-2.4 0-1.3 1.5-2.4 3.5-2.4 1.9-.2 3.7.9 3.7 2.4zm-13.7-1.1c-.4 1.3-2.4 1.9-4.1 1.3-1.9-.4-3.2-1.9-2.8-3.2.4-1.3 2.4-1.9 4.1-1.5 2 .6 3.3 2.1 2.8 3.4zm-12.3-5.4c-.9 1.1-2.8.9-4.3-.6-1.5-1.3-1.9-3.2-.9-4.1.9-1.1 2.8-.9 4.3.6 1.3 1.3 1.8 3.3.9 4.1zm-9.1-9.1c-.9.6-2.6 0-3.7-1.5s-1.1-3.2 0-3.9c1.1-.9 2.8-.2 3.7 1.3 1.1 1.5 1.1 3.3 0 4.1zm-6.5-9.7c-.9.9-2.4.4-3.5-.6-1.1-1.3-1.3-2.8-.4-3.5.9-.9 2.4-.4 3.5.6 1.1 1.3 1.3 2.8.4 3.5zm-6.7-7.4c-.4.9-1.7 1.1-2.8.4-1.3-.6-1.9-1.7-1.5-2.6.4-.6 1.5-.9 2.8-.4 1.3.7 1.9 1.8 1.5 2.6z"/></svg>
  </div>
  <div class="md-source__repository">
    jingzhian/mkdocs-md-notes
  </div>
</a>
      </div>
    
  </nav>
</header>
    
    <div class="md-container" data-md-component="container">
      
        
      
      
        
          

<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-tabs__inner md-grid">
    <ul class="md-tabs__list">
      
        
  <li class="md-tabs__item">
    
      <a href=".." class="md-tabs__link md-tabs__link--active">
        Home
      </a>
    
  </li>

      
        
      
        
      
        
      
        
      
        
      
        
      
        
      
        
      
        
      
        
      
        
      
        
      
        
      
        
  
  
    <li class="md-tabs__item">
      
        <a href="../dermatology/" class="md-tabs__link">
          UWorld Complete
        </a>
      
    </li>
  

      
        
  
  
    <li class="md-tabs__item">
      
        <a href="../temp-notes/" class="md-tabs__link">
          Temporary notes
        </a>
      
    </li>
  

      
        
  
  
    <li class="md-tabs__item">
      
        <a href="../ENT/" class="md-tabs__link">
          Unorganized
        </a>
      
    </li>
  

      
        
  
  
    <li class="md-tabs__item">
      
        <a href="../approach/" class="md-tabs__link">
          Tools
        </a>
      
    </li>
  

      
        
  
  
    <li class="md-tabs__item">
      
        <a href="../fammed/" class="md-tabs__link">
          Conditions
        </a>
      
    </li>
  

      
        
  
  
    <li class="md-tabs__item">
      
        <a href="../tech-notes/" class="md-tabs__link">
          Beyond Clinical
        </a>
      
    </li>
  

      
    </ul>
  </div>
</nav>
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              <div class="md-sidebar md-sidebar--primary" data-md-component="navigation">
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    <nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="https://jingzhian.github.io/mkdocs-md-notes/" title="Clinical Medicine Notes" class="md-nav__button md-logo" aria-label="Clinical Medicine Notes">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 003-3 3 3 0 00-3-3 3 3 0 00-3 3 3 3 0 003 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54z"/></svg>

    </a>
    Clinical Medicine Notes
  </label>
  
    <div class="md-nav__source">
      
<a href="https://github.com/jingzhian/mkdocs-md-notes/" title="Go to repository" class="md-source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path d="M400 32H48C21.5 32 0 53.5 0 80v352c0 26.5 21.5 48 48 48h352c26.5 0 48-21.5 48-48V80c0-26.5-21.5-48-48-48zM277.3 415.7c-8.4 1.5-11.5-3.7-11.5-8 0-5.4.2-33 .2-55.3 0-15.6-5.2-25.5-11.3-30.7 37-4.1 76-9.2 76-73.1 0-18.2-6.5-27.3-17.1-39 1.7-4.3 7.4-22-1.7-45-13.9-4.3-45.7 17.9-45.7 17.9-13.2-3.7-27.5-5.6-41.6-5.6-14.1 0-28.4 1.9-41.6 5.6 0 0-31.8-22.2-45.7-17.9-9.1 22.9-3.5 40.6-1.7 45-10.6 11.7-15.6 20.8-15.6 39 0 63.6 37.3 69 74.3 73.1-4.8 4.3-9.1 11.7-10.6 22.3-9.5 4.3-33.8 11.7-48.3-13.9-9.1-15.8-25.5-17.1-25.5-17.1-16.2-.2-1.1 10.2-1.1 10.2 10.8 5 18.4 24.2 18.4 24.2 9.7 29.7 56.1 19.7 56.1 19.7 0 13.9.2 36.5.2 40.6 0 4.3-3 9.5-11.5 8-66-22.1-112.2-84.9-112.2-158.3 0-91.8 70.2-161.5 162-161.5S388 165.6 388 257.4c.1 73.4-44.7 136.3-110.7 158.3zm-98.1-61.1c-1.9.4-3.7-.4-3.9-1.7-.2-1.5 1.1-2.8 3-3.2 1.9-.2 3.7.6 3.9 1.9.3 1.3-1 2.6-3 3zm-9.5-.9c0 1.3-1.5 2.4-3.5 2.4-2.2.2-3.7-.9-3.7-2.4 0-1.3 1.5-2.4 3.5-2.4 1.9-.2 3.7.9 3.7 2.4zm-13.7-1.1c-.4 1.3-2.4 1.9-4.1 1.3-1.9-.4-3.2-1.9-2.8-3.2.4-1.3 2.4-1.9 4.1-1.5 2 .6 3.3 2.1 2.8 3.4zm-12.3-5.4c-.9 1.1-2.8.9-4.3-.6-1.5-1.3-1.9-3.2-.9-4.1.9-1.1 2.8-.9 4.3.6 1.3 1.3 1.8 3.3.9 4.1zm-9.1-9.1c-.9.6-2.6 0-3.7-1.5s-1.1-3.2 0-3.9c1.1-.9 2.8-.2 3.7 1.3 1.1 1.5 1.1 3.3 0 4.1zm-6.5-9.7c-.9.9-2.4.4-3.5-.6-1.1-1.3-1.3-2.8-.4-3.5.9-.9 2.4-.4 3.5.6 1.1 1.3 1.3 2.8.4 3.5zm-6.7-7.4c-.4.9-1.7 1.1-2.8.4-1.3-.6-1.9-1.7-1.5-2.6.4-.6 1.5-.9 2.8-.4 1.3.7 1.9 1.8 1.5 2.6z"/></svg>
  </div>
  <div class="md-source__repository">
    jingzhian/mkdocs-md-notes
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
      


  <li class="md-nav__item">
    <a href=".." title="Home" class="md-nav__link">
      Home
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../biomed-sciences/" title="Basics of Anatomy, Physiology & Pathology" class="md-nav__link">
      Basics of Anatomy, Physiology & Pathology
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../clinic-foundation/" title="Foundation of Clinical Medicine" class="md-nav__link">
      Foundation of Clinical Medicine
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../encounter/" title="Bedside Etiquette" class="md-nav__link">
      Bedside Etiquette
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../neurology/" title="Neurology" class="md-nav__link">
      Neurology
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../endocrinology/" title="Endocrinology" class="md-nav__link">
      Endocrinology
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../urorenal/" title="Urorenal" class="md-nav__link">
      Urorenal
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../obstetrics/" title="Obstetrics" class="md-nav__link">
      Obstetrics
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../hematology/" title="Hematology" class="md-nav__link">
      Hematology
    </a>
  </li>

    
      
      
      

  


  <li class="md-nav__item md-nav__item--active">
    
    <input class="md-nav__toggle md-toggle" data-md-toggle="toc" type="checkbox" id="__toc">
    
      
    
    
      <label class="md-nav__link md-nav__link--active" for="__toc">
        Oncology
        <span class="md-nav__icon md-icon">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 9h14V7H3v2m0 4h14v-2H3v2m0 4h14v-2H3v2m16 0h2v-2h-2v2m0-10v2h2V7h-2m0 6h2v-2h-2v2z"/></svg>
        </span>
      </label>
    
    <a href="./" title="Oncology" class="md-nav__link md-nav__link--active">
      Oncology
    </a>
    
      
<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
      </span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#paraneoplastic-conditions" class="md-nav__link">
    Paraneoplastic Conditions
  </a>
  
    <nav class="md-nav" aria-label="Paraneoplastic Conditions">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#non-specific-symptoms" class="md-nav__link">
    Non-specific symptoms
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cachexia" class="md-nav__link">
    Cachexia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#anemia" class="md-nav__link">
    Anemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hypercoagulability" class="md-nav__link">
    Hypercoagulability
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#malignant-ascites" class="md-nav__link">
    Malignant Ascites
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#malignant-pleural-effusion" class="md-nav__link">
    Malignant Pleural Effusion
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hypercalcemia-due-to-malignancy" class="md-nav__link">
    Hypercalcemia due to Malignancy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#superior-vena-cava-obstruction" class="md-nav__link">
    Superior Vena Cava Obstruction
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#spinal-cord-compression" class="md-nav__link">
    Spinal Cord Compression
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#treatment-related-conditions" class="md-nav__link">
    Treatment Related Conditions
  </a>
  
    <nav class="md-nav" aria-label="Treatment Related Conditions">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#tumor-lysis-syndrome" class="md-nav__link">
    Tumor Lysis Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neutropenic-fever-or-sepsis" class="md-nav__link">
    Neutropenic Fever or Sepsis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#thyroid-dysfunction" class="md-nav__link">
    Thyroid Dysfunction
  </a>
  
    <nav class="md-nav" aria-label="Thyroid Dysfunction">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cancer-immunotherapy-induced-primary-hypothyroidism" class="md-nav__link">
    Cancer immunotherapy induced primary hypothyroidism
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#bgit" class="md-nav__link">
    BGIT
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#central-nervous-system-tumors" class="md-nav__link">
    Central Nervous System Tumors
  </a>
  
    <nav class="md-nav" aria-label="Central Nervous System Tumors">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#schwannoma" class="md-nav__link">
    Schwannoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#cardiac-tumors" class="md-nav__link">
    Cardiac Tumors
  </a>
  
    <nav class="md-nav" aria-label="Cardiac Tumors">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cardiac-fibroma" class="md-nav__link">
    Cardiac fibroma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#lung-cancers" class="md-nav__link">
    Lung Cancers
  </a>
  
    <nav class="md-nav" aria-label="Lung Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#mesothelioma" class="md-nav__link">
    Mesothelioma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#muciepidermoid-carcinoma" class="md-nav__link">
    Muciepidermoid carcinoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#superior-pulmonary-sulcus-pancoast-tumor" class="md-nav__link">
    Superior pulmonary sulcus (Pancoast) tumor
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#bronchial-carcinoid-tumor" class="md-nav__link">
    Bronchial Carcinoid Tumor
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#gastroenteric-cancers" class="md-nav__link">
    Gastroenteric Cancers
  </a>
  
    <nav class="md-nav" aria-label="Gastroenteric Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#esophageal-ca" class="md-nav__link">
    Esophageal CA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#stomach-ca" class="md-nav__link">
    Stomach CA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#colon-ca" class="md-nav__link">
    Colon CA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rectal-ca" class="md-nav__link">
    Rectal CA
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#endocrine-cancers" class="md-nav__link">
    Endocrine Cancers
  </a>
  
    <nav class="md-nav" aria-label="Endocrine Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#carcinoid-tumor" class="md-nav__link">
    Carcinoid Tumor
  </a>
  
    <nav class="md-nav" aria-label="Carcinoid Tumor">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#carcinoid-sydnromes" class="md-nav__link">
    Carcinoid Sydnromes
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pheochromocytoma" class="md-nav__link">
    Pheochromocytoma
  </a>
  
    <nav class="md-nav" aria-label="Pheochromocytoma">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hypertensive-crisis-in-pheochromocytoma" class="md-nav__link">
    Hypertensive Crisis in Pheochromocytoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#renal-cancers" class="md-nav__link">
    Renal Cancers
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#urological-cancers" class="md-nav__link">
    Urological Cancers
  </a>
  
    <nav class="md-nav" aria-label="Urological Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#prostate-cancer" class="md-nav__link">
    Prostate Cancer
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#testicular-tumor" class="md-nav__link">
    Testicular Tumor
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#gynecological-cancers" class="md-nav__link">
    Gynecological Cancers
  </a>
  
    <nav class="md-nav" aria-label="Gynecological Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#risk-factors-comparison" class="md-nav__link">
    Risk Factors Comparison
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#endocrine-cancers_1" class="md-nav__link">
    Endocrine Cancers
  </a>
  
    <nav class="md-nav" aria-label="Endocrine Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#carcinoid-tumor_1" class="md-nav__link">
    Carcinoid tumor
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pheochromocytoma_1" class="md-nav__link">
    Pheochromocytoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#haematological-malignancies" class="md-nav__link">
    Haematological Malignancies
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#muscularskeletal-cancers" class="md-nav__link">
    Muscularskeletal Cancers
  </a>
  
    <nav class="md-nav" aria-label="Muscularskeletal Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#chondrosarcoma" class="md-nav__link">
    Chondrosarcoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#sgh-lymphoma-team" class="md-nav__link">
    SGH Lymphoma Team
  </a>
  
    <nav class="md-nav" aria-label="SGH Lymphoma Team">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#people" class="md-nav__link">
    People
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#general" class="md-nav__link">
    General
  </a>
  
    <nav class="md-nav" aria-label="General">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#maintain-team-list-optional" class="md-nav__link">
    Maintain team list (optional)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#discharge-and-summaries" class="md-nav__link">
    Discharge and Summaries
  </a>
  
    <nav class="md-nav" aria-label="Discharge and Summaries">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#logistics-of-discharge" class="md-nav__link">
    Logistics of discharge
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#discharge-summary" class="md-nav__link">
    Discharge Summary
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#management-newly-diagnosed-lymphoma" class="md-nav__link">
    Management - newly diagnosed lymphoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#chemotherapy-regimes" class="md-nav__link">
    Chemotherapy Regimes
  </a>
  
    <nav class="md-nav" aria-label="Chemotherapy Regimes">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#r-chop" class="md-nav__link">
    R-CHOP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#iv-methotrexate" class="md-nav__link">
    IV METHOTREXATE
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cisplatin" class="md-nav__link">
    Cisplatin
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#ifosfamide-eg-in-ice-ivac" class="md-nav__link">
    Ifosfamide eg in ICE / IVAC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#general-notes" class="md-nav__link">
    General Notes
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures" class="md-nav__link">
    Procedures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#resources-and-numbers" class="md-nav__link">
    Resources and Numbers
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
    
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../msk/" title="Msk" class="md-nav__link">
      Msk
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../rheumatology/" title="Rheumatology" class="md-nav__link">
      Rheumatology
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../psychiatry/" title="None" class="md-nav__link">
      None
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item">
    <a href="../palliative/" title="Palliative Care" class="md-nav__link">
      Palliative Care
    </a>
  </li>

    
      
      
      


  <li class="md-nav__item md-nav__item--nested">
    
      <input class="md-nav__toggle md-toggle" data-md-toggle="nav-15" type="checkbox" id="nav-15">
    
    <label class="md-nav__link" for="nav-15">
      UWorld Complete
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M8.59 16.58L13.17 12 8.59 7.41 10 6l6 6-6 6-1.41-1.42z"/></svg>
      </span>
    </label>
    <nav class="md-nav" aria-label="UWorld Complete" data-md-level="1">
      <label class="md-nav__title" for="nav-15">
        <span class="md-nav__icon md-icon">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
        </span>
        UWorld Complete
      </label>
      <ul class="md-nav__list" data-md-scrollfix>
        
        
          
          
          


  <li class="md-nav__item">
    <a href="../dermatology/" title="Dermatology" class="md-nav__link">
      Dermatology
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../psychiatry/" title="Psychiatry" class="md-nav__link">
      Psychiatry
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../ophthalmology/" title="Ophthalmology" class="md-nav__link">
      Ophthalmology
    </a>
  </li>

        
      </ul>
    </nav>
  </li>

    
      
      
      


  <li class="md-nav__item md-nav__item--nested">
    
      <input class="md-nav__toggle md-toggle" data-md-toggle="nav-16" type="checkbox" id="nav-16">
    
    <label class="md-nav__link" for="nav-16">
      Temporary notes
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M8.59 16.58L13.17 12 8.59 7.41 10 6l6 6-6 6-1.41-1.42z"/></svg>
      </span>
    </label>
    <nav class="md-nav" aria-label="Temporary notes" data-md-level="1">
      <label class="md-nav__title" for="nav-16">
        <span class="md-nav__icon md-icon">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
        </span>
        Temporary notes
      </label>
      <ul class="md-nav__list" data-md-scrollfix>
        
        
          
          
          


  <li class="md-nav__item">
    <a href="../temp-notes/" title="Temp notes" class="md-nav__link">
      Temp notes
    </a>
  </li>

        
      </ul>
    </nav>
  </li>

    
      
      
      


  <li class="md-nav__item md-nav__item--nested">
    
      <input class="md-nav__toggle md-toggle" data-md-toggle="nav-17" type="checkbox" id="nav-17">
    
    <label class="md-nav__link" for="nav-17">
      Unorganized
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M8.59 16.58L13.17 12 8.59 7.41 10 6l6 6-6 6-1.41-1.42z"/></svg>
      </span>
    </label>
    <nav class="md-nav" aria-label="Unorganized" data-md-level="1">
      <label class="md-nav__title" for="nav-17">
        <span class="md-nav__icon md-icon">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
        </span>
        Unorganized
      </label>
      <ul class="md-nav__list" data-md-scrollfix>
        
        
          
          
          


  <li class="md-nav__item">
    <a href="../ENT/" title="None" class="md-nav__link">
      None
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../anesthesiology/" title="None" class="md-nav__link">
      None
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../fammed/" title="None" class="md-nav__link">
      None
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../pharmaco/" title="None" class="md-nav__link">
      None
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../reproductive/" title="Reproductive" class="md-nav__link">
      Reproductive
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../respiratory/" title="Respiratory" class="md-nav__link">
      Respiratory
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../accident/" title="Accident" class="md-nav__link">
      Accident
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../approach-signs/" title="Signs" class="md-nav__link">
      Signs
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../cardiology/" title="Cardiology" class="md-nav__link">
      Cardiology
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../career/" title="None" class="md-nav__link">
      None
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../clinical-scores/" title="Clinical Scores" class="md-nav__link">
      Clinical Scores
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../devices/" title="Medical Devices" class="md-nav__link">
      Medical Devices
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../gastroenterology/" title="Gastroenterology" class="md-nav__link">
      Gastroenterology
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../general-medicine/" title="General Medicine" class="md-nav__link">
      General Medicine
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../genetics-immune/" title="Genetics immune" class="md-nav__link">
      Genetics immune
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../infectious-diseases/" title="Infectious Diseases" class="md-nav__link">
      Infectious Diseases
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../pain-management/" title="General Pain Management" class="md-nav__link">
      General Pain Management
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../pediatrics/" title="Pediatrics" class="md-nav__link">
      Pediatrics
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../people/" title="Ophthalmology" class="md-nav__link">
      Ophthalmology
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../procedures/" title="None" class="md-nav__link">
      None
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../rehabilitation/" title="Rehabilitation" class="md-nav__link">
      Rehabilitation
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../residency/" title="Career" class="md-nav__link">
      Career
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../system-checklist/" title="Onsite Learning Checklist" class="md-nav__link">
      Onsite Learning Checklist
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../trauma/" title="Trauma and Accidents" class="md-nav__link">
      Trauma and Accidents
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../vascular/" title="Vascular" class="md-nav__link">
      Vascular
    </a>
  </li>

        
      </ul>
    </nav>
  </li>

    
      
      
      


  <li class="md-nav__item md-nav__item--nested">
    
      <input class="md-nav__toggle md-toggle" data-md-toggle="nav-18" type="checkbox" id="nav-18">
    
    <label class="md-nav__link" for="nav-18">
      Tools
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M8.59 16.58L13.17 12 8.59 7.41 10 6l6 6-6 6-1.41-1.42z"/></svg>
      </span>
    </label>
    <nav class="md-nav" aria-label="Tools" data-md-level="1">
      <label class="md-nav__title" for="nav-18">
        <span class="md-nav__icon md-icon">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
        </span>
        Tools
      </label>
      <ul class="md-nav__list" data-md-scrollfix>
        
        
          
          
          


  <li class="md-nav__item">
    <a href="../approach/" title="Approach" class="md-nav__link">
      Approach
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../approach-symptoms/" title="Approach to Symptoms" class="md-nav__link">
      Approach to Symptoms
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../physicalexam/" title="Physical Examination" class="md-nav__link">
      Physical Examination
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../electrophys/" title="Electrophysiology" class="md-nav__link">
      Electrophysiology
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../investigations/" title="Investigations" class="md-nav__link">
      Investigations
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../pharmaco/" title="Pharmaco" class="md-nav__link">
      Pharmaco
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../procedures/" title="Procedures" class="md-nav__link">
      Procedures
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../surgery/" title="Surgery" class="md-nav__link">
      Surgery
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../imaging/" title="Imaging" class="md-nav__link">
      Imaging
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../labs/" title="Bloods and Labs" class="md-nav__link">
      Bloods and Labs
    </a>
  </li>

        
      </ul>
    </nav>
  </li>

    
      
      
      


  <li class="md-nav__item md-nav__item--nested">
    
      <input class="md-nav__toggle md-toggle" data-md-toggle="nav-19" type="checkbox" id="nav-19">
    
    <label class="md-nav__link" for="nav-19">
      Conditions
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M8.59 16.58L13.17 12 8.59 7.41 10 6l6 6-6 6-1.41-1.42z"/></svg>
      </span>
    </label>
    <nav class="md-nav" aria-label="Conditions" data-md-level="1">
      <label class="md-nav__title" for="nav-19">
        <span class="md-nav__icon md-icon">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
        </span>
        Conditions
      </label>
      <ul class="md-nav__list" data-md-scrollfix>
        
        
          
          
          


  <li class="md-nav__item">
    <a href="../fammed/" title="Fammed" class="md-nav__link">
      Fammed
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../anesthesiology/" title="Anesthesiology" class="md-nav__link">
      Anesthesiology
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../ENT/" title="ENT" class="md-nav__link">
      ENT
    </a>
  </li>

        
      </ul>
    </nav>
  </li>

    
      
      
      


  <li class="md-nav__item md-nav__item--nested">
    
      <input class="md-nav__toggle md-toggle" data-md-toggle="nav-20" type="checkbox" id="nav-20">
    
    <label class="md-nav__link" for="nav-20">
      Beyond Clinical
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M8.59 16.58L13.17 12 8.59 7.41 10 6l6 6-6 6-1.41-1.42z"/></svg>
      </span>
    </label>
    <nav class="md-nav" aria-label="Beyond Clinical" data-md-level="1">
      <label class="md-nav__title" for="nav-20">
        <span class="md-nav__icon md-icon">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
        </span>
        Beyond Clinical
      </label>
      <ul class="md-nav__list" data-md-scrollfix>
        
        
          
          
          


  <li class="md-nav__item">
    <a href="../tech-notes/" title="Technical Notes" class="md-nav__link">
      Technical Notes
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../healthcare-system/" title="Healthcare system" class="md-nav__link">
      Healthcare system
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../frontiers/" title="Frontiers" class="md-nav__link">
      Frontiers
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../career/" title="Exam Information" class="md-nav__link">
      Exam Information
    </a>
  </li>

        
          
          
          


  <li class="md-nav__item">
    <a href="../sgh-dsml/" title="DSML Notes" class="md-nav__link">
      DSML Notes
    </a>
  </li>

        
      </ul>
    </nav>
  </li>

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              <div class="md-sidebar md-sidebar--secondary" data-md-component="toc">
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    
<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
      </span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#paraneoplastic-conditions" class="md-nav__link">
    Paraneoplastic Conditions
  </a>
  
    <nav class="md-nav" aria-label="Paraneoplastic Conditions">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#non-specific-symptoms" class="md-nav__link">
    Non-specific symptoms
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cachexia" class="md-nav__link">
    Cachexia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#anemia" class="md-nav__link">
    Anemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hypercoagulability" class="md-nav__link">
    Hypercoagulability
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#malignant-ascites" class="md-nav__link">
    Malignant Ascites
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#malignant-pleural-effusion" class="md-nav__link">
    Malignant Pleural Effusion
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hypercalcemia-due-to-malignancy" class="md-nav__link">
    Hypercalcemia due to Malignancy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#superior-vena-cava-obstruction" class="md-nav__link">
    Superior Vena Cava Obstruction
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#spinal-cord-compression" class="md-nav__link">
    Spinal Cord Compression
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#treatment-related-conditions" class="md-nav__link">
    Treatment Related Conditions
  </a>
  
    <nav class="md-nav" aria-label="Treatment Related Conditions">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#tumor-lysis-syndrome" class="md-nav__link">
    Tumor Lysis Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neutropenic-fever-or-sepsis" class="md-nav__link">
    Neutropenic Fever or Sepsis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#thyroid-dysfunction" class="md-nav__link">
    Thyroid Dysfunction
  </a>
  
    <nav class="md-nav" aria-label="Thyroid Dysfunction">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cancer-immunotherapy-induced-primary-hypothyroidism" class="md-nav__link">
    Cancer immunotherapy induced primary hypothyroidism
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#bgit" class="md-nav__link">
    BGIT
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#central-nervous-system-tumors" class="md-nav__link">
    Central Nervous System Tumors
  </a>
  
    <nav class="md-nav" aria-label="Central Nervous System Tumors">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#schwannoma" class="md-nav__link">
    Schwannoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#cardiac-tumors" class="md-nav__link">
    Cardiac Tumors
  </a>
  
    <nav class="md-nav" aria-label="Cardiac Tumors">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cardiac-fibroma" class="md-nav__link">
    Cardiac fibroma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#lung-cancers" class="md-nav__link">
    Lung Cancers
  </a>
  
    <nav class="md-nav" aria-label="Lung Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#mesothelioma" class="md-nav__link">
    Mesothelioma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#muciepidermoid-carcinoma" class="md-nav__link">
    Muciepidermoid carcinoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#superior-pulmonary-sulcus-pancoast-tumor" class="md-nav__link">
    Superior pulmonary sulcus (Pancoast) tumor
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#bronchial-carcinoid-tumor" class="md-nav__link">
    Bronchial Carcinoid Tumor
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#gastroenteric-cancers" class="md-nav__link">
    Gastroenteric Cancers
  </a>
  
    <nav class="md-nav" aria-label="Gastroenteric Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#esophageal-ca" class="md-nav__link">
    Esophageal CA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#stomach-ca" class="md-nav__link">
    Stomach CA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#colon-ca" class="md-nav__link">
    Colon CA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rectal-ca" class="md-nav__link">
    Rectal CA
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#endocrine-cancers" class="md-nav__link">
    Endocrine Cancers
  </a>
  
    <nav class="md-nav" aria-label="Endocrine Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#carcinoid-tumor" class="md-nav__link">
    Carcinoid Tumor
  </a>
  
    <nav class="md-nav" aria-label="Carcinoid Tumor">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#carcinoid-sydnromes" class="md-nav__link">
    Carcinoid Sydnromes
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pheochromocytoma" class="md-nav__link">
    Pheochromocytoma
  </a>
  
    <nav class="md-nav" aria-label="Pheochromocytoma">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hypertensive-crisis-in-pheochromocytoma" class="md-nav__link">
    Hypertensive Crisis in Pheochromocytoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#renal-cancers" class="md-nav__link">
    Renal Cancers
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#urological-cancers" class="md-nav__link">
    Urological Cancers
  </a>
  
    <nav class="md-nav" aria-label="Urological Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#prostate-cancer" class="md-nav__link">
    Prostate Cancer
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#testicular-tumor" class="md-nav__link">
    Testicular Tumor
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#gynecological-cancers" class="md-nav__link">
    Gynecological Cancers
  </a>
  
    <nav class="md-nav" aria-label="Gynecological Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#risk-factors-comparison" class="md-nav__link">
    Risk Factors Comparison
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#endocrine-cancers_1" class="md-nav__link">
    Endocrine Cancers
  </a>
  
    <nav class="md-nav" aria-label="Endocrine Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#carcinoid-tumor_1" class="md-nav__link">
    Carcinoid tumor
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pheochromocytoma_1" class="md-nav__link">
    Pheochromocytoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#haematological-malignancies" class="md-nav__link">
    Haematological Malignancies
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#muscularskeletal-cancers" class="md-nav__link">
    Muscularskeletal Cancers
  </a>
  
    <nav class="md-nav" aria-label="Muscularskeletal Cancers">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#chondrosarcoma" class="md-nav__link">
    Chondrosarcoma
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#sgh-lymphoma-team" class="md-nav__link">
    SGH Lymphoma Team
  </a>
  
    <nav class="md-nav" aria-label="SGH Lymphoma Team">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#people" class="md-nav__link">
    People
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#general" class="md-nav__link">
    General
  </a>
  
    <nav class="md-nav" aria-label="General">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#maintain-team-list-optional" class="md-nav__link">
    Maintain team list (optional)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#discharge-and-summaries" class="md-nav__link">
    Discharge and Summaries
  </a>
  
    <nav class="md-nav" aria-label="Discharge and Summaries">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#logistics-of-discharge" class="md-nav__link">
    Logistics of discharge
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#discharge-summary" class="md-nav__link">
    Discharge Summary
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#management-newly-diagnosed-lymphoma" class="md-nav__link">
    Management - newly diagnosed lymphoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#chemotherapy-regimes" class="md-nav__link">
    Chemotherapy Regimes
  </a>
  
    <nav class="md-nav" aria-label="Chemotherapy Regimes">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#r-chop" class="md-nav__link">
    R-CHOP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#iv-methotrexate" class="md-nav__link">
    IV METHOTREXATE
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cisplatin" class="md-nav__link">
    Cisplatin
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#ifosfamide-eg-in-ice-ivac" class="md-nav__link">
    Ifosfamide eg in ICE / IVAC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#general-notes" class="md-nav__link">
    General Notes
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures" class="md-nav__link">
    Procedures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#resources-and-numbers" class="md-nav__link">
    Resources and Numbers
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          <div class="md-content">
            <article class="md-content__inner md-typeset">
              
                
                  <a href="https://github.com/jingzhian/mkdocs-md-notes/edit/master/docs/oncology.md" title="Edit this page" class="md-content__button md-icon">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20.71 7.04c.39-.39.39-1.04 0-1.41l-2.34-2.34c-.37-.39-1.02-.39-1.41 0l-1.84 1.83 3.75 3.75M3 17.25V21h3.75L17.81 9.93l-3.75-3.75L3 17.25z"/></svg>
                  </a>
                
                
                  
                
                
                <h1 id="oncology">Oncology<a class="headerlink" href="#oncology" title="Permanent link">&para;</a></h1>
<ul>
<li>Palliative chemotherapy: patient is not </li>
<li>Curative chemotherapy: Adjuvant chemotherapy vs Neo-adjuvant chemotherapy</li>
<li><strong>Neoadjuvant</strong> therapy encompasses all treatments that are administered before the primary cancer treatment, whereas <strong>adjuvant</strong> therapy describes regimens administered after the primary treatment.</li>
</ul>
<h2 id="paraneoplastic-conditions">Paraneoplastic Conditions<a class="headerlink" href="#paraneoplastic-conditions" title="Permanent link">&para;</a></h2>
<p>Divide into general conditions that applies for most cancers and some cancer specific problems</p>
<h3 id="non-specific-symptoms">Non-specific symptoms<a class="headerlink" href="#non-specific-symptoms" title="Permanent link">&para;</a></h3>
<ul>
<li>coma and death</li>
<li>neuropsychiatric conditions</li>
<li>GI disturbances</li>
<li>renal failure</li>
</ul>
<h3 id="cachexia">Cachexia<a class="headerlink" href="#cachexia" title="Permanent link">&para;</a></h3>
<p>This is itself a syndrome, characterized by loss of body weight of 10%, reduced food intake and systemic inflammation</p>
<ul>
<li>Adipose tissue loss due to Zinc-&alpha;2-glycoprotein, inhibition of lipoprotein lipase by cytokines (TNF-&alpha;, IL-1, IFN-&alpha;),<strong>Cori cycle is the main metablism pathway of tumor and is only performing glycolysis</strong>, Uncoupling proteins UCP1-UCP5 in mitochondrial inner mmb results in a lack of ATP production</li>
<li>Decreased protein synthesis not corrected by dietary supplementation plus increased protein catabolism; Proteolysis-inducing factor by tumor, cytokines (TNF-&alpha;, IFN-&alpha;); Activate NF-&kappa;&beta; and proteosome degradation ubiquitination of myofibrillar proteins</li>
</ul>
<h3 id="anemia">Anemia<a class="headerlink" href="#anemia" title="Permanent link">&para;</a></h3>
<p>Chronic production of acute phase markers, IL-6 decreases iron circulation and TNF etc decreases body response to EPO</p>
<h3 id="hypercoagulability">Hypercoagulability<a class="headerlink" href="#hypercoagulability" title="Permanent link">&para;</a></h3>
<p>Increased risk of DVT and PE due to</p>
<ul>
<li>
<p>Extrinsic vascular compression / invasion</p>
</li>
<li>
<p>Tissue factor production by tumor and endothelial cells</p>
</li>
<li>
<p>Accentuated platelet activation and accumulation</p>
</li>
<li>
<p>Expression of phosyphatidyl serine that supports prothrombinase and tenase activity, inflammation-mediated increase in factor VIII, fibrinogen and von Willebrand factor</p>
</li>
<li>
<p>Impaired endogenous fibrinolysis due to excess level of plasminogen activator-inhibitor 1</p>
</li>
</ul>
<h3 id="malignant-ascites">Malignant Ascites<a class="headerlink" href="#malignant-ascites" title="Permanent link">&para;</a></h3>
<p>See ascites</p>
<h3 id="malignant-pleural-effusion">Malignant Pleural Effusion<a class="headerlink" href="#malignant-pleural-effusion" title="Permanent link">&para;</a></h3>
<p>See pleural effusion</p>
<h3 id="hypercalcemia-due-to-malignancy">Hypercalcemia due to Malignancy<a class="headerlink" href="#hypercalcemia-due-to-malignancy" title="Permanent link">&para;</a></h3>
<p>Most common metabolic abnormality -- 10% of cancers</p>
<ul>
<li>Osteoclast resorption of bone due to endocrine (PTH) and paracine (local factors from bone mets inc RANKL, IL-1, TNF-&alpha;, TGF-&alpha;) effects</li>
</ul>
<p>It occurs either in the presence of skeletal metastases or in their absence in patients who have humoural hypercalcemia of malignancy. Tumour derived parathyroid hormone related peptide plays a major role in both types. Common tumour types include myeloma, breast, renal, lung, and thyroid cancer.
 Symptoms range from mild to severe: nausea, anorexia, constipation, polyuria, thirst, lethargy, confusion, stupor, seizures, arrhythmias and coma.</p>
<p>Decision to treat must take into consideration the potential benefits (improved symptoms) versus burdens of therapy (taking blood/administering fluids and medication); the patient's disease trajectory and the overall goals of care. Urgency of treatment depends on the severity of hypercalcemia and the associated symptoms.</p>
<p><strong>Suggested Workflow</strong></p>
<ol>
<li>
<p>Check corrected calcium + renal function. Start IV hydration with 1-3L 0.9% NaCl for confirmed hypercalcemia and monitor Intake/Output to ensure negative balance. Stop calcium supplements. Eliminate precipitating factors</p>
</li>
<li>
<p>Then for Severely symptomatic patient or corrected calcium &gt; 3.5mmol/L: <strong>IV bisphosphonate</strong></p>
</li>
<li>
<p>Recheck calcium after 3-5days (or recheck earlier if calcitonin is used)</p>
</li>
<li>
<p>At all times (until calcium has normalized), continue <strong>rehydration</strong> and await bisphosphonate effect (Bisphosphonates work within 1 week).</p>
</li>
<li>
<p><strong>Calcitonin</strong> use can be considered if patients are very symptomatic from hypercalcemia and the symptoms need to be controlled fast. </p>
<ul>
<li>
<p>It can be started at SC 4IU/kg q12h. . Calcium should be rechecked after 1-2 days &rarr; If no response, consider increase calcitonin dose to 8IU/Kg q 12h &rarr; recheck calcium after another 1-2 days &rarr; if no response, increase calcitonin to 8IU/kg q6h.</p>
</li>
<li>
<p>NB: Calcitonin has a short onset and duration of action (hours) and with repeated doses (within 48hours) tachyphylaxis will develop and it becomes ineffective.</p>
</li>
</ul>
</li>
<li>
<p>Once calcium normal, hydration can be stopped. Continue monitoring of calcium; ensure precipitating factors eliminated.</p>
</li>
<li>
<p>Asymptomatic/mildly symptomatic patients with corrected calcium 2.6 – 3.5mmol/L: recheck calcium/renal function 1 day after rehydration. If still raised &gt;3mmol/L or patient still symptomatic - give IV bisphosphonate</p>
</li>
<li>
<p>Recheck calcium after 3-5 days.</p>
<ul>
<li>If normal: continue to monitor calcium levels; can stop hydration; ensure precipitating factors eliminated</li>
<li>If still elevated (but less than pre- treatment levels), continue hydration -&gt; recheck after 2-3 days. Bisphosphonates can't be repeated until 7 days after first dose so as to avoid hypocalcemia.</li>
<li>If still elevated (and more than pre -treatment levels) - -&gt; continue hydration. Consider adjuncts e.g. steroids in patients with hematological malignancies as they have anti-neoplastic effects. Consider repeating bisphosphonates and use of more potent bisphosphonates 7 days after the first dose has been given or if need for calcitonin treatment. Also consider if there’s a possibility of anti-neoplastic treatment. Get expert advice.</li>
</ul>
</li>
</ol>
<p><strong>Notes regarding bisphosphonates</strong></p>
<ul>
<li>
<p><strong>Most serious adverse effect is renal failure</strong>. Depending of degree of pre-existing renal failure, bisphosphonates might need dose reduction or might be contraindicated. They have poor oral bioavailability so the parenteral route is preferred.</p>
</li>
<li>
<p>Available agents are clodronate, pamidronate and zolendronate. Clodronate can be given po or s/c. Pamidronate and zolendronate are intravenous (though there are case reports of pamidronate being given s/c) and are commonly used in SGH. Relative potency of clodronate: pamidronate: zolendronate is 1:10:1000</p>
</li>
<li>
<p>Usual doses:</p>
</li>
<li>
<p><strong>Clodronate</strong>: 1500mg given s/c or IV in 250-500ml NaCL over 4 hours as a single dose or 300mg once daily over 2-6hours(and not to be repeated for &gt;7-10days); usual duration of effect: 2 weeks</p>
<table>
<thead>
<tr>
<th>Calculated creatinine clearance</th>
<th>Renal Dose Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCT 50-80ml/min</td>
<td>75% to 100% of normal dose</td>
</tr>
<tr>
<td>12-49ml/min</td>
<td>50-75% of normal dose</td>
</tr>
<tr>
<td>&lt;12ml/min</td>
<td>50% of normal dose</td>
</tr>
</tbody>
</table>
</li>
<li>
<p><strong>Pamidronate</strong>: 30-90mg IV (in 250ml to 500ml NaCL over 60-90mins) (calcium 2.6 - 3mmol/L: 30mg; 3.0-3.5mmol/L: 60mg; &gt;3.5mmol/L: 90mg); usual duration of effect: 3-4 weeks</p>
<ul>
<li>When CCT &lt; 30 ml/min: If benefits outweigh risk, run infusion over a longer period: e.g. 90mg over 4-6 hours (maximum is 20mg/hr)</li>
</ul>
</li>
<li>
<p><strong>Zolendronate</strong>: 4mg in 100ml NaCl given IV over 15mins; usual duration of effect 4-6 weeks</p>
<table>
<thead>
<tr>
<th>Calculated creatinine clearance</th>
<th>Renal Dose Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCT &gt;60 ml/min</td>
<td>No dose reduction</td>
</tr>
<tr>
<td>CCT 50 - 60 ml/min</td>
<td>3.5 mg</td>
</tr>
<tr>
<td>CCT 40 - 49 ml/min</td>
<td>3.3 mg</td>
</tr>
<tr>
<td>CCT 30 - 39 ml/min</td>
<td>3 mg</td>
</tr>
<tr>
<td>CCT &lt;30 ml/min</td>
<td>Use not recommended</td>
</tr>
</tbody>
</table>
</li>
</ul>
<h3 id="superior-vena-cava-obstruction">Superior Vena Cava Obstruction<a class="headerlink" href="#superior-vena-cava-obstruction" title="Permanent link">&para;</a></h3>
<p>Superior Vena Cava Obstruction (SVCO) is due to compression or invasion of the SVC by mediastinal lymph nodes or tumour in the region of the right main bronchus. Severity of symptoms depends on degree and speed of narrowing of SVC.</p>
<p>Causes</p>
<ul>
<li>90% caused by malignant tumours</li>
<li>85% by lung cancer (small cell lung cancer, squamous-cell lung cancer) o Malignant lymphomas</li>
<li>&lt; 2% thymoma or germ cell tumours</li>
<li>Other metastatic tumours</li>
<li>Non-malignant</li>
<li>Long –term central venous catheters causing thrombus</li>
</ul>
<p><strong>Presentation (Signs and Symptoms)</strong></p>
<ul>
<li>General inspection: facial swelling, peri-orbital edema, fixed distended neck veins</li>
<li>HEENT: Headache, dizziness, pressure in head and face, visual changes</li>
<li>Cardiorespiratory: cyanosis, dyspnea</li>
<li>Extremities: Upper limb oedema disproportionate to lower limb edema</li>
<li>Action: Pemberton sign</li>
</ul>
<p><strong>Diagnosis</strong></p>
<ul>
<li>Mainly clinical</li>
<li>CT Scan most useful</li>
<li>Reveals site of obstruction and collateral flow</li>
<li>Differentiate extrinsic compression by tumour from thrombosis</li>
<li>Information about tumour mass</li>
<li>Guide for fine needle aspiration biopsy if histological diagnosis needed</li>
</ul>
<p><strong>Management</strong></p>
<ul>
<li>Elevate head</li>
<li>Assessment of worsening neurological, pulmonary and cardiac function</li>
<li>No upper limb cannulas (acceptable on lower limbs)</li>
<li>Symptomatic treatment</li>
<li><strong>Oxygen</strong> therapy and allay anxiety</li>
<li>Patients should be started on <strong>steroids</strong> as soon as possible (Dexamethasone 16mg daily)</li>
<li>Subsequently further treatment decisions will involve </li>
<li>radiologically-guided stenting (useful in severe respiratory distress) or radiotherapy. </li>
<li>Chemotherapy can be considered in patients with chemo sensitive tumours. </li>
<li>If the obstruction is due to a thrombus – patients should be anti-coagulated unless contraindicated.</li>
</ul>
<h3 id="spinal-cord-compression">Spinal Cord Compression<a class="headerlink" href="#spinal-cord-compression" title="Permanent link">&para;</a></h3>
<p>Malignant spinal cord compression occurs when the dural sac and its contents are compressed at the level of the cord or cauda equina.</p>
<ul>
<li>It affects about 3‐5% of patients with cancer &amp; 10% of patients with spinal metastases.</li>
<li>Cord compression can be the initial presentation of cancer.</li>
<li>Late diagnosis (more than 48hrs) is common causing permanent loss of function and significant morbidity.</li>
</ul>
<p>Signs &amp; Symptoms</p>
<ul>
<li>Back pain (present in 90% of cases) “band‐like” OR “electric‐shock” incident pain</li>
<li>Leg weakness</li>
<li>Increased reflexes (Upper motor neuron signs below level of compression)</li>
<li>Sensory level</li>
<li>Urinary hesitancy/bowel incontinence (late feature in SCC/early feature in cauda equina)</li>
</ul>
<p>Distribution</p>
<ul>
<li>Thoracic spine – 70%, as it has a smaller ratio of spinal canal to cord diameter than the other two spinal segments</li>
<li>Multiple contiguous levels – 10% to 38%.</li>
<li>Lumbosacral spine – 20%</li>
<li>Cervical spine – 10%.</li>
</ul>
<p>Incidence in Malignancy</p>
<ul>
<li>Lung – 16%</li>
<li>Breast – 12%</li>
<li>Unknown primary – 11%</li>
<li>Lymphoma – 11%</li>
<li>Myeloma – 9%</li>
</ul>
<p>Assessment</p>
<ol>
<li>Rule out trauma: ask for any fall /injury to lower back</li>
<li>Get a comprehensive pain history</li>
<li>Please refer to pain section for information on pain assessment</li>
<li>Perform a physical examination with emphasis on neurological assessment of the upper and lower limbs</li>
<li>Assess power to determine myotomes involved</li>
<li>Assess sensory level to determine dermatomal distribution</li>
<li>Look out for spinal tenderness (can point towards a vertebral collapse)</li>
<li>Assess urinary and bowel continence</li>
<li>Any difficulties micturating/opening bowels</li>
<li>Check for bladder and perform a per rectal examination to look for lax anal tone/saddle anesthesia</li>
<li>CT / MRI scan</li>
<li>Urgent referral for CT scans and MRI improves early detection (within 48hrs). MRI scans are more sensitive than CT Scans and are the gold standard for diagnosis.</li>
<li>Usually recommend whole spine imaging in malignant disease because multiple levels can be at risk.</li>
</ol>
<p><strong>Management</strong></p>
<ul>
<li>Start I.V. corticosteroids (IV Dexamethasone 16mg/24hrs)</li>
<li>Rationale: Shown to improve neurologic function and relieve pain by reducing oedema.</li>
<li>Assess Spinal Stability with Spinal Instability Neoplastic Score</li>
<li>Calculate Tokuhashi score: a prognostication tool that helps with decision-making regarding surgical intervention.</li>
<li>Assess extent of neurological deficits. If deficits are severe and &gt;48hours, chance of neurological recovery is very low with RT or surgery. However RT may still be given for pain control if pain is an issue (in absence of spinal instability)</li>
<li>See table below for proposed management, if neurological deficits are mild OR &lt; 48hours :</li>
<li>Urgent consultation by Radiation Oncologist (especially for radiosensitive tumour and no spinal instability) and Orthopedic/Spinal Surgeons (especially for spinal instability)</li>
<li><strong>Rationale for RT</strong>: ICORG 05-03 and SCORAD III Randomised controlled trials have shown equivalence in terms of the proportion of patients ambulating after single fraction of RT versus multiple fractions. As such, unless patients have a longer survival, where tumour control with a longer course of RT is important, a single fraction should be given</li>
<li>
<p><strong>Rationale for surgery</strong>: Surgery is the first choice where the site of the primary tumour is unknown. In cases of spinal instability or compression at a previously irradiated site, surgery is likely to give the best outcome but other factors such as ECOG status; prognosis and patient’s wishes need to be considered. Surgery should also be considered when neurological symptoms progress during radiotherapy, or where tumours are not radiosensitive.</p>
</li>
<li>
<table>
<thead>
<tr>
<th></th>
<th>Stable Spine (SINS&lt;7)</th>
<th>Unstable spine (SINS &geq; 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good Prognosis (Tokuhashi &geq; 9)</td>
<td>Single Level : Surgery followed by radiotherapy (RT ); Multiple levels : RT alone</td>
<td>Surgery followed by post operative RT</td>
</tr>
<tr>
<td>Poor Prognosis (Tokuhashi &lt;9)</td>
<td>RT alone or Supportive Care</td>
<td>Orthopaedic consult for spine stabilization &plusmn; RT or Supportive Care</td>
</tr>
</tbody>
</table>
</li>
</ul>
<h2 id="treatment-related-conditions">Treatment Related Conditions<a class="headerlink" href="#treatment-related-conditions" title="Permanent link">&para;</a></h2>
<h3 id="tumor-lysis-syndrome">Tumor Lysis Syndrome<a class="headerlink" href="#tumor-lysis-syndrome" title="Permanent link">&para;</a></h3>
<ul>
<li>Defined biochemically as elevation in potassium, phosphate and uric acid and decrease in calcium level</li>
<li>Defined clinically when patient develops arrhythmia, acute kidney injury and etc</li>
<li>Risks of tumour lysis usually intermediate to high with aggressive lymphoma</li>
<li>Ensure all patients who are newly diagnosed or newly started on treatment, </li>
<li>Are on a 1.5 – 2L drip</li>
<li>
<p>Unless there are contraindications, they should be placed on allopurinol prophylaxis (300mg OM for those with normal renal function) at least for the first cycle of their treatment (usually for 14 days)</p>
</li>
<li>
<p>TLS bloods should be performed <strong>twice a day for the first few days</strong> when a patient is newly initiated on treatment. This frequency can be tailed down if patient remains stable. </p>
</li>
</ul>
<h3 id="neutropenic-fever-or-sepsis">Neutropenic Fever or Sepsis<a class="headerlink" href="#neutropenic-fever-or-sepsis" title="Permanent link">&para;</a></h3>
<p>Medical emergency. </p>
<p><strong>Management</strong></p>
<ul>
<li>Start Antibiotics</li>
<li>Ensure patient has <strong>broad spectrum</strong> antibiotics that covers for gram-negative and pseudomonas aeruginosae (e.g. tazocin, cefepime and amikacin) within 1 hour of the fever</li>
<li><strong>Vancomycin</strong> is indicated in the following scenarios:<ul>
<li>Hypotensive or severe sepsis</li>
<li>Suspicion of line sepsis (NOT ALL patient with a line and neutropenic sepsis needs vancomycin)</li>
<li>Severe mucositis (which increases risk of streptococci spp infection)</li>
<li>Pneumonia</li>
</ul>
</li>
<li>
<p>Consider <strong>antifungal</strong> if the patient is persistently febrile after 48 hours of broad spectrum antibiotics or is neutropenic for more than 4 – 5 days</p>
</li>
<li>
<p>Ensure patient receives <strong>IV fluids</strong> (30mL/kg) within the first 1 hour</p>
</li>
<li>Start patient on <strong>GCSF 300mg</strong> even if the patient has had pegylated GCSF a few days ago</li>
<li>Granulocyte colony-stimulating factor, also known as colony-stimulating factor 3, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.- Granulocyte-colony stimulating factor (G-CSF) mobilizes and increases the amount of hematopoietic stem cells in peripheral blood</li>
<li>The pegylated G-CSF has longer half-life and is given once only, which is more comfortable for patients, whereas the non-pegylated requires multiple daily injection because of its short half-life.</li>
</ul>
<h3 id="thyroid-dysfunction">Thyroid Dysfunction<a class="headerlink" href="#thyroid-dysfunction" title="Permanent link">&para;</a></h3>
<h4 id="cancer-immunotherapy-induced-primary-hypothyroidism">Cancer immunotherapy induced primary hypothyroidism<a class="headerlink" href="#cancer-immunotherapy-induced-primary-hypothyroidism" title="Permanent link">&para;</a></h4>
<p><em>Case: 70 year old man, chronic smoker, suffers from increasing tiredness, cold intolerance, and constipation over the past few weeks. Since his diagnosis of advanced cancer 5 month ago, which was not surgical amenable, he has completed a course of whole brain RT (WBRT), and has been receiving regular systemic cancer therapy. His recent thyroid function shows: TSH 48 [range 0.65 - 4.5 mIU/L], and free T4 3.6 [range, 8.8 - 14.4 pmol/L]</em></p>
<h3 id="bgit">BGIT<a class="headerlink" href="#bgit" title="Permanent link">&para;</a></h3>
<p>Maintain high suspicion for BGIT and perforation especially in patients who just received chemotherapy for lymphoma that involves the gastrointestinal tract. </p>
<h2 id="central-nervous-system-tumors">Central Nervous System Tumors<a class="headerlink" href="#central-nervous-system-tumors" title="Permanent link">&para;</a></h2>
<h3 id="schwannoma">Schwannoma<a class="headerlink" href="#schwannoma" title="Permanent link">&para;</a></h3>
<ul>
<li>Diagnosis: S100 stain</li>
</ul>
<h2 id="cardiac-tumors">Cardiac Tumors<a class="headerlink" href="#cardiac-tumors" title="Permanent link">&para;</a></h2>
<h3 id="cardiac-fibroma">Cardiac fibroma<a class="headerlink" href="#cardiac-fibroma" title="Permanent link">&para;</a></h3>
<ul>
<li>Compromise cardiac function, lead to arrhythmia</li>
</ul>
<h2 id="lung-cancers">Lung Cancers<a class="headerlink" href="#lung-cancers" title="Permanent link">&para;</a></h2>
<p>General approach to lung parenchymal cancers</p>
<ul>
<li>
<p>Small cell lung cancer (SCLC) vs Non-small cell lung cancer (NSCLC)</p>
<ul>
<li>Papillary Carcinoma of the Lung</li>
</ul>
</li>
<li>
<p>If NSCLC: mets w/u to determine resectable or non-resectable</p>
</li>
<li>
<p>If SCLC: determine RT vs. no RT depending on limited or extensive disease (extending beyond 1 hemi-thorax)</p>
</li>
</ul>
<h3 id="mesothelioma">Mesothelioma<a class="headerlink" href="#mesothelioma" title="Permanent link">&para;</a></h3>
<ul>
<li>Complication: Compression of the lung</li>
</ul>
<p>Mesothelioma is a malignant neoplasm derived from the mesothelial lining of the thoracic cavity. It is strongly linked to asbestos exposure and usually presents with cough, chest pain, and dyspnea. Chest imaging typically reveals pleural thickening with an effusion.</p>
<h3 id="muciepidermoid-carcinoma">Muciepidermoid carcinoma<a class="headerlink" href="#muciepidermoid-carcinoma" title="Permanent link">&para;</a></h3>
<ul>
<li>Obstruction of the bronchus</li>
</ul>
<h3 id="superior-pulmonary-sulcus-pancoast-tumor">Superior pulmonary sulcus (Pancoast) tumor<a class="headerlink" href="#superior-pulmonary-sulcus-pancoast-tumor" title="Permanent link">&para;</a></h3>
<p><strong>Clinical Features</strong></p>
<ul>
<li>Shoulder pain due to invasion of the <strong>brachial plexus</strong>, pleura, ribs, or vertebral bodies. Because shoulder pain is common and often due to a benign cause (eg, osteoarthritis), the diagnosis of Pancoast tumor is frequently delayed.</li>
<li>Horner syndrome due to invasion of paravertebral sympathetic chain/stellate ganglion</li>
<li>Ipsilateral ptosis, miosis, enophthalmos &amp; anhidrosis</li>
<li>Neurologic symptoms in the arm (invasion of C8-T2 nerves)</li>
<li>Weakness/atrophy of intrinsic hand muscles</li>
<li>Pain/paresthesia of 4<sup>th</sup>/5<sup>th</sup> digits &amp; medial arm/forearm</li>
<li>in an ulnar distribution due to invasion of the inferior (C8-T1) portion of the brachial plexus</li>
<li>Supraclavicular lymphadenopathy</li>
<li>Hoarseness due to recurrent laryngeal nerve invasion</li>
<li>Superior vena cava syndrome</li>
<li>Weight loss is also common; pulmonary symptoms (eg, cough) do not typically occur until the tumor is large (as in this patient).</li>
</ul>
<h3 id="bronchial-carcinoid-tumor">Bronchial Carcinoid Tumor<a class="headerlink" href="#bronchial-carcinoid-tumor" title="Permanent link">&para;</a></h3>
<p>Bronchial carcinoid tumors are rare and usually occur centrally in the central airways, not the lung apex. Most cases present with hemoptysis, cough, or dyspnea from denudation/obstruction of the airway.</p>
<h2 id="gastroenteric-cancers">Gastroenteric Cancers<a class="headerlink" href="#gastroenteric-cancers" title="Permanent link">&para;</a></h2>
<p>Upper GI</p>
<h3 id="esophageal-ca">Esophageal CA<a class="headerlink" href="#esophageal-ca" title="Permanent link">&para;</a></h3>
<p>infection from abcess formation</p>
<h3 id="stomach-ca">Stomach CA<a class="headerlink" href="#stomach-ca" title="Permanent link">&para;</a></h3>
<p><strong>GIST</strong></p>
<ul>
<li>Diagnosis: c-KIT</li>
</ul>
<h3 id="colon-ca">Colon CA<a class="headerlink" href="#colon-ca" title="Permanent link">&para;</a></h3>
<h3 id="rectal-ca">Rectal CA<a class="headerlink" href="#rectal-ca" title="Permanent link">&para;</a></h3>
<ul>
<li>Often kills by hemorrhage because the tumor barrow through the intestinal wall.</li>
</ul>
<h2 id="endocrine-cancers">Endocrine Cancers<a class="headerlink" href="#endocrine-cancers" title="Permanent link">&para;</a></h2>
<h3 id="carcinoid-tumor">Carcinoid Tumor<a class="headerlink" href="#carcinoid-tumor" title="Permanent link">&para;</a></h3>
<ul>
<li>
<p>Amyloidosis for Multiple Myeloma / Plasmacytoma</p>
<ul>
<li>Generally there is deposition of protin in &beta; pleated sheets from the tumor</li>
<li>Or if plasma cells then there is deposition of immunoglobulin</li>
</ul>
</li>
</ul>
<h4 id="carcinoid-sydnromes">Carcinoid Sydnromes<a class="headerlink" href="#carcinoid-sydnromes" title="Permanent link">&para;</a></h4>
<h3 id="pheochromocytoma">Pheochromocytoma<a class="headerlink" href="#pheochromocytoma" title="Permanent link">&para;</a></h3>
<h4 id="hypertensive-crisis-in-pheochromocytoma">Hypertensive Crisis in Pheochromocytoma<a class="headerlink" href="#hypertensive-crisis-in-pheochromocytoma" title="Permanent link">&para;</a></h4>
<h2 id="renal-cancers">Renal Cancers<a class="headerlink" href="#renal-cancers" title="Permanent link">&para;</a></h2>
<h2 id="urological-cancers">Urological Cancers<a class="headerlink" href="#urological-cancers" title="Permanent link">&para;</a></h2>
<h3 id="prostate-cancer">Prostate Cancer<a class="headerlink" href="#prostate-cancer" title="Permanent link">&para;</a></h3>
<p>Commonly are adenocarcinomas arising from peripheral zone of the gland</p>
<ul>
<li>
<p>Presentation</p>
<ul>
<li>
<p>BOO: frequency, hesitancy, nocturia,</p>
</li>
<li>
<p>Hematuria</p>
</li>
</ul>
</li>
<li>
<p>PE:</p>
<ul>
<li>Digital rectal examination -- asymmetric nodular enlargement</li>
</ul>
</li>
<li>
<p>Dx:</p>
<ul>
<li>
<p>PSA elevation</p>
</li>
<li>
<p>Increased prostate acid phosphatase (advanced disease -- when tumor penetrate capsule)</p>
</li>
<li>
<p>Increased alkaline phosphatase</p>
</li>
</ul>
</li>
<li>
<p>Tx:</p>
<ul>
<li></li>
</ul>
</li>
<li>
<p>Px / Cx:</p>
<ul>
<li>
<p>Metastasize to bone and produce sclerotic lesion</p>
</li>
<li>
<p>Post prostate / bladder surgery may be complicated with vesicoureteral reflux</p>
</li>
</ul>
</li>
</ul>
<h3 id="testicular-tumor">Testicular Tumor<a class="headerlink" href="#testicular-tumor" title="Permanent link">&para;</a></h3>
<p>Testicular Tumor Risk Factors The most common testicular tumor is germ cell tumor. The specific cause of germ cell tumors is unknown, but various factors have been associated with the increased risk.</p>
<p>Genetics play a role in testicular cancer risk. Klinefelter's syndrome (47xxy) is associated with a higher incidence of germ cell tumors. For first degree relatives of individuals affected there is approximately six to ten- fold increased risk for germ cell tumors. Other conditions such as Down syndrome, testicular feminizing syndrome, true hermaphrodites, persistent mullerian syndrome, and cutaneous ichthyosis are at higher risk for developing germ cell tumors.</p>
<p>Family history also plays an important role in testicular cancer risk. There have been reports of six-fold increased risk among male offspring of a patient with testicular cancer.</p>
<p>Patients with cryptorchidism have 20 to 40-fold increased risk compared with their normal counterparts. Cryptorchidism is the absence of one or both testes from the scrotum, usually as the result of an undescended testis.Orchipexy, even at an early age, appears to reduce the incidence of germ cell tumor only slightly.</p>
<p>Numerous environmental hazards, such as industrial occupations and drug exposures have been implicated in the development of testicular cancer. They include DES, Agent Orange, and solvents used to clean jets and ochratoxin A.</p>
<p>One to two percent of patients with testicular cancer will develop a second primary cancer in the contralateral testicle. This represents a 500-fold increase in risk compared with normal population.</p>
<p>Prior trauma, elevated scrotal temperature, and recurrent activities, such as horseback riding and motorcycle riding do not appear to be related to the development of testicular tumors.</p>
<p>Testicular tumor presents as scrotal mass that is rarely accompanied by tenderness.</p>
<p>The swelling is solid so should not transilluminate.</p>
<p>A testicular tumor is usually non-tender to palpation</p>
<p>Testicular cancer is the most common malignancy affecting males between the ages 15 and 35, although it accounts for only one percent of all cancers in men.</p>
<p>These tumors could present as a nodule or as a painless swelling of the testicle, 30-40% may present with dull ache or heavy sensation in the lower abdomen, perianal area, or scrotum areas. Acute pain is the presenting symptom in ten percent of cases.</p>
<p>There is no evidence to support routine screening for testicular cancer in asymptomatic adolescents and young adults.</p>
<p>Three Types of Testicular Tumors Germ cell tumor (GCT)</p>
<p>Seminomatous (SGCT)</p>
<p>Nonseminomatous (NSGCT)</p>
<p>Germ cell tumors (GCTs) are the most common-accounting for (95%) of primary testicular tumors-and are classified as either seminomas (45%) or others (50%), called nonseminomatous germ cell tumors, or NSGCT, based on histology.</p>
<p>Distribution of nonseminomatous germ cell tumors (NSGCTs):</p>
<p>Embryonal cell tumor, the classic pure-cell NSGCT (20%)</p>
<p>Mixed GCTs (40%)</p>
<p>Teratomas and teratocarcinomas (30%)</p>
<p>Yolk sac tumors (also known as endodermal sinus tumors) are the most common prepubertal GCTs. They may be benign but are most often malignant. Most affected patients require surgery and chemotherapy because of the aggressive nature of the tumors, but the overall prognosis is excellent.</p>
<p>Choriocarcinoma is the most lethal but least common NSGCT (1%)</p>
<p>Non-germ cell tumors</p>
<p>Non-germ cell tumors (Leydig cell tumors and Sertoli cell tumors) constitute the remaining 5% of primary testicular tumors; these are rare tumors that are malignant in only about 10% of the cases.</p>
<p>Extragonadal</p>
<p>Lymphoma, leukemia, and melanoma are the most common malignancies that metastasize to the testicle (extragonadal tumors)</p>
<h2 id="gynecological-cancers">Gynecological Cancers<a class="headerlink" href="#gynecological-cancers" title="Permanent link">&para;</a></h2>
<h3 id="risk-factors-comparison">Risk Factors Comparison<a class="headerlink" href="#risk-factors-comparison" title="Permanent link">&para;</a></h3>
<p>Cancer                              Risk</p>
<hr />
<p>Epithelial Ovarian CA               Nulliparous despite ovulatory cycles
  Endometrial CA                      Estrogen only therapy
  Vaginal Squamous Cell               Age > 60, HPV, Smoking
  Vaginal Clear Cell Adenocarcinoma   In utero DES exposure</p>
<h2 id="endocrine-cancers_1">Endocrine Cancers<a class="headerlink" href="#endocrine-cancers_1" title="Permanent link">&para;</a></h2>
<h3 id="carcinoid-tumor_1">Carcinoid tumor<a class="headerlink" href="#carcinoid-tumor_1" title="Permanent link">&para;</a></h3>
<p>Serotonin production results in carcinoid syndrome.</p>
<ul>
<li>
<p>Presentation:</p>
<ul>
<li>Carcinoid heart disease: Fibrosis of valves, primarily affecting tricuspid and pulmonic valve (unless there is tumor in the lung / shunt</li>
</ul>
</li>
</ul>
<h3 id="pheochromocytoma_1">Pheochromocytoma<a class="headerlink" href="#pheochromocytoma_1" title="Permanent link">&para;</a></h3>
<h2 id="haematological-malignancies">Haematological Malignancies<a class="headerlink" href="#haematological-malignancies" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute Leukemia: Blocked hematopoiesis with increased blasts and cytopenia in peripheral blood.</li>
</ul>
<h2 id="muscularskeletal-cancers">Muscularskeletal Cancers<a class="headerlink" href="#muscularskeletal-cancers" title="Permanent link">&para;</a></h2>
<h3 id="chondrosarcoma">Chondrosarcoma<a class="headerlink" href="#chondrosarcoma" title="Permanent link">&para;</a></h3>
<ul>
<li>Pathological fracture of the bone</li>
</ul>
<h2 id="sgh-lymphoma-team">SGH Lymphoma Team<a class="headerlink" href="#sgh-lymphoma-team" title="Permanent link">&para;</a></h2>
<h3 id="people">People<a class="headerlink" href="#people" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Team</th>
<th>Consultant</th>
<th>Reg</th>
<th>Resident</th>
<th>MO</th>
<th>HO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ng Quan Sing</td>
<td>Sheryl Santos</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="general">General<a class="headerlink" href="#general" title="Permanent link">&para;</a></h3>
<p>Many patients are on ongoing chemotherapy, usually they cycle every 3 weeks, some every 4 weeks. You will get to know your lymphoma patients very well. Usually they are seen in clinic prior to their admission for chemotherapy. From clinic, consultants will fax off their chemo order protocol. Haem pharmacy (ext 4559) has a cut off time for chemo orders ie 4.30pm. The moment you sense patients on your radar, call haem pharmacy and check if they have the chemo order form. If not, you have to get hold of a registrar ASAP to write up the chemo for the patients. </p>
<p>If patients are admitted a day or so after their clinic appointment, their NCC folder will be sent to ward 48 so you can retrieve it from there. </p>
<p>All outpatient clinic notes (this is super handy) are documented in clindoc and rarely do you have to sweat over not having old notes and not knowing what your consultant wants. Most of the consultants will be quite clear in what they want for their patient’s admission and what their plans are for TCU, scans, readmission etc.</p>
<h4 id="maintain-team-list-optional">Maintain team list (optional)<a class="headerlink" href="#maintain-team-list-optional" title="Permanent link">&para;</a></h4>
<table>
<thead>
<tr>
<th>Location  Initials  Age/Gender  Primary consultant</th>
<th>Onco Hx  PMHx</th>
<th>Acute issues</th>
<th>Chemo date  Abx</th>
<th>Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>I would recommend maintain a combined list that is updated on Monday and Thursday evening. Can email to all the registrars and MOs. You will love it when you have to present the cases on Friday team meeting and round over the weekend, as well as when the team list gets heavy.</p>
<h3 id="discharge-and-summaries">Discharge and Summaries<a class="headerlink" href="#discharge-and-summaries" title="Permanent link">&para;</a></h3>
<h4 id="logistics-of-discharge">Logistics of discharge<a class="headerlink" href="#logistics-of-discharge" title="Permanent link">&para;</a></h4>
<ul>
<li>On discharge, ensure</li>
<li>TCU dates given</li>
<li>Bloods are ordered prior to next TCU</li>
<li>Restaging CT scans ordered (only after specific cycles, usually 2, 4 and at the end of treatment) </li>
<li>Readmission form is given if patient is to be admitted again</li>
<li>Chemotherapy bookings at ATU</li>
<li>Please remind patients to do their blood tests at NCC and not any other places</li>
<li>Patients who have blood tests without appointments should be instructed to inform the nurses to update the lymphoma team registrar of the blood tests. (e.g. mid-cycles check) </li>
</ul>
<h4 id="discharge-summary">Discharge Summary<a class="headerlink" href="#discharge-summary" title="Permanent link">&para;</a></h4>
<p><strong><em>Chemotherapy</em></strong></p>
<p>Must document clearly chemotherapy given</p>
<ul>
<li>Pre-medications given (rationale if more is given. E.g. previous adverse reactions)</li>
<li>Chemotherapy (current body surface area, dose / m2, actual dose given)</li>
<li>Dose adjustments made must be explained</li>
<li>Any side effects experienced</li>
</ul>
<p>Example 1</p>
<ul>
<li>Started on Cycle 1 ABVD, D1 on 26/7/19 based on BSA 1.57m2 Height 170cm, Weight 52.2 kg</li>
<li>Pre-medications: IV granisetron 3mg, IV dexamethasone 8mg, IV diphenhydramine 25mg, PO paracetamol 1g </li>
<li><strong>Granisetron</strong> is a serotonin 5-HT₃ receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata.</li>
<li>IV Doxorubicin 39mg (25mg/m2), IV Bleomycin 15 units (10units/m2), IV Vinblastine 9mg (6mg/m2), IV Dacarbazine 580mg (375mg/m2)</li>
</ul>
<p>Example 2</p>
<ul>
<li>Vincristine (represented by O in the regime R-EPCH) omitted in view of G2 peripheral neuropathy   </li>
<li>Underwent C5 R-EPCH inpatient (D1 = 28/08/2019) </li>
<li>Height 155cm, weight 50.1kg, BSA 1.47m2 </li>
<li>Premeds: IV diphenhydramine 25mg on D1, IV hydrocortisone 100mg on D1, PO paracetamol 1g on D1, IV granisetron 1mg daily D1-5</li>
<li>Therapy<ul>
<li>IV rituximab 600mg on D1 </li>
<li>IV etoposide 110mg (75mg/m2/day) on D1-4</li>
<li>IV doxorubicin 20mg (14mg/m2/day) on D1-4</li>
<li>IV cyclophosphamide 1580mg (1080mg/m2) on D5 </li>
</ul>
</li>
<li>PO dexamethasone 8mg OM and 4mg every afternoon D1-5 (in replacement of dose equivalent prednisolone 30mg/m2 BD to reduce pill burden) </li>
<li>Complicated by severe nausea and vomiting</li>
<li>To add Aprepitant 125mg on D1 and 80mg D2 to D3 next cycle as pre-medications</li>
</ul>
<p><strong>Oncological History</strong></p>
<ul>
<li>To update the treatment given during the admission on the oncological history prior to discharge</li>
<li>Generally the following headings will be useful</li>
<li>Initial presentation and date of diagnosis (usually date of histology)</li>
<li>Histology description</li>
<li>Treatment and progress / Latest scans<ul>
<li>This can be done chronologically</li>
</ul>
</li>
</ul>
<p>Example</p>
<ol>
<li>Classical Hodgkin lymphoma, nodular sclerosis subtype. </li>
<li>
<p>Stage 4B (advanced)</p>
</li>
<li>
<p>Hassenclever IPs score = 5 (5YPFS 42% eOS 56%) (age, leukocytosis, stage IV, hemoglobin, albumin)</p>
</li>
<li>
<p>Site of disease: Spleen, lymphadenopathy above and below diaphragm, bone marrow</p>
<p>a.  <strong>Initial presentation</strong></p>
</li>
<li>
<p>21/7/18 -- 26/7/18 KTPH Gen Surg for RIF pain 2/7 with guarding. TW 17.19. </p>
<ul>
<li>21/7/18 CT TAP Thin-rim enhancing mild hypodense retroperitoneal lesion in the right iliac fossa with marked adjoining fat stranding is probably inflammatory in nature. Associated right iliac and inguinal lymphadenopathy. Appendix is not identified.</li>
<li>22/7/18 VIR percutaneous drainage of RIF collection </li>
<li>25/7/18 VIR guided biopsy of abdominal mass</li>
<li>Histology abdominal mass biopsies. Necro-Inflammatory tissue only.</li>
</ul>
</li>
<li>15/11/18: Presented with right SCV mass, LOW, fever<ul>
<li>FNAC Right supraclavicular lymph node, FNA: Reactive lymph node</li>
<li>CT TAP (19/12/18) performed: Bilateral lower cervical and mediastinal lymphadenopathy</li>
<li>Defaulted excision biopsy</li>
</ul>
</li>
<li>Admitted 20/5/19 - 24/5/19 Khoo Teck Puat Hospital for Non vertiginous giddiness  intermittent fever x 2/52, dry cough, sore throat LOW ~ 5kg over 2-3 months </li>
<li>19/6/19 Right supraclavicular lymph node, excision biopsy (KS19-03255): Classical Hodgkin lymphoma, nodular sclerosis subtype</li>
</ol>
<p>b. <strong>Initial Investigations / Staging:</strong></p>
<ul>
<li>
<p>Stage 4B</p>
</li>
<li>
<p>PET/CT (18/7/19) Extensive <strong>hypermetabolic adenopathy</strong> seen above and below the diaphragm in keeping with submitted history of Hodgkin's disease. There are several FDG-avid lesions within the unenlarged spleen. Diffuse, patchy increased FDG uptake throughout the axial and proximal appendicular skeleton is suspicious for disease involvement. Tiny foci of FDG uptake in the right hepatic lobe are CT occult and indeterminate in nature. </p>
</li>
<li>
<p>15/7/19: ESR 134 Hb 9.8 TW 21.15 Albumin 28 LDH 486</p>
</li>
<li>
<p>Hep B core total antibody negative, surface antigen negative, HIV and Hep C negative</p>
</li>
<li>
<p>Echo (10/7/19) LVEF 64% </p>
</li>
<li>
<p>Lung function (27/7/19) DL/VA 1.60 (97%), DLCO(uncorrected) 6.04 (86%).</p>
<p>c. <strong>Treatment and Progress</strong></p>
</li>
<li>
<p>Planned to initiate ABVD 25/7/19 for 6 cycles with interim PET-scan after 2 cycles</p>
</li>
<li>27/7/19 #1 ABVD </li>
</ul>
<h3 id="management-newly-diagnosed-lymphoma">Management - newly diagnosed lymphoma<a class="headerlink" href="#management-newly-diagnosed-lymphoma" title="Permanent link">&para;</a></h3>
<p>Please ensure the following tests are done or if not then please order. </p>
<table>
<thead>
<tr>
<th>Basic Tests</th>
<th><strong>Why</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FBC/Renal panel/Liver panel</td>
<td>Baseline  prior to start of chemoRx</td>
</tr>
<tr>
<td>Uric acid/Calcium/PO4</td>
<td>Tumour lysis syndrome (TLS)</td>
</tr>
<tr>
<td>LDH</td>
<td>TLS  &amp; prognostic</td>
</tr>
<tr>
<td>PT/APTT</td>
<td>Prep for bone marrow</td>
</tr>
<tr>
<td>Hep B surface Ab, Hep B surface Antigen, Hep B  core total Ab</td>
<td>Risk  of activation esp with rituximab</td>
</tr>
<tr>
<td>Anti HCV / HIV status</td>
<td>↑ risk of NHL</td>
</tr>
<tr>
<td>CT PNS/T/A/P or PET/CT</td>
<td>For  staging according to Ann Arbor</td>
</tr>
<tr>
<td>Bone marrow for Aspiration, Cytogenetics / Karyotype, Flow cytometry, and Histology</td>
<td>For staging</td>
</tr>
<tr>
<td>2DE</td>
<td>Baseline  cardiac function prior to treatment with anthracyclines</td>
</tr>
<tr>
<td><strong>IF  ADVANCED STAGE / BM involvement / sanctuary sites eg sinus, kidneys, testis,  spine etc</strong></td>
<td></td>
</tr>
<tr>
<td>Lumbar Puncture: FEME, Cytology (at least 50 drops to be collected in  each bottle if after hours in the green liquid), Flow cytometry</td>
<td></td>
</tr>
<tr>
<td><strong>IF  HODGKIN’S DISEASE ALSO:</strong></td>
<td></td>
</tr>
<tr>
<td>ESR</td>
<td>Prognostic</td>
</tr>
<tr>
<td>Lung function test</td>
<td>Baseline prior to treatment  with bleomycin</td>
</tr>
</tbody>
</table>
<p><em>All histology including CSF cytology and particularly bone marrow trephine and tissue biopsies are to be made to the attention of our haempathologist: **Dr Leonard Tan*</em> or <strong>Dr. Cheng Chee Leong (just write Lymphoma Team).</strong> PLEASE DO NOT WRITE URGENT ON THE FORM UNLESS EXPLICITLY TOLD TO DO SO BY YOUR CON! For Sarcoma samples, write attention to Sarcoma Team. </p>
<h3 id="chemotherapy-regimes">Chemotherapy Regimes<a class="headerlink" href="#chemotherapy-regimes" title="Permanent link">&para;</a></h3>
<p>Only ward 48/72/77/78 have nurses trained in giving chemo. If you have a patient in overflows whom will require chemotherapy, get them to these wards and ask for height and weight to be done. This is required to calculate body surface area to dose chemo.</p>
<p><strong>BSA = square root of {[ Ht (cm) x Wt (kg) ] / 3600} (Motsellar formula)</strong></p>
<h4 id="r-chop">R-CHOP<a class="headerlink" href="#r-chop" title="Permanent link">&para;</a></h4>
<p>Commonest lymphoma = DLBCL </p>
<p>RCHOP is pretty much standard of care for DLBCL. R = rituximab (CD 20 monoclonal antibody) C = cyclophosphamide H = doxorubicin **H**ydrochloride O = vincristine aka **O**ncovin &amp; P = prednisolone </p>
<p><strong>What to watch for</strong></p>
<ul>
<li>
<p>Remember doxorubicin is a <strong>vesicant</strong> (as is vincristine). If it extravasates = extensive necrosis.</p>
</li>
<li>
<p>To avoid extravasation</p>
<ul>
<li>Ensure there is a peripheral plug that is working well</li>
<li>Ensure good intact vein with good backflow of blood </li>
<li>Insertion site should not be distal to a recent venipuncture or in an arm with compromised circulation (think of requesting groin central line in SVCO)</li>
</ul>
</li>
<li>
<p>If extravasates:</p>
<ul>
<li><strong>Doxorubicin:</strong> Stop injecting immediately &rarr; stop IV infusion &rarr; aspirate as much drug out as possible with clean syringe &rarr; apply DMSO 99% topical solution (4 drops per 10cm2 of skin) &rarr; allow DMSO to air dry &rarr; elevate limb and apply <strong>COLD</strong> compress</li>
<li><strong>Vincristine:</strong> As above except no DMSO and apply <strong>WARM</strong> compress</li>
</ul>
<p><strong>OBSERVE CLOSELY. CALL ONCO REG, CALL SURGEON IF WORSENING TISSUE INJURY</strong></p>
</li>
<li>
<p><strong>Rituximab infusion related reactions</strong> can be as high as 80% and can be severe. You will be called for urticaria, dyspnea, bronchospasm, angioedema, hypotension, tachycardia, back or abdo pain or discomfort or arrest. </p>
</li>
<li>
<p>If reaction is moderate: stop infusion &rarr; give Benadryl 25mg bolus &rarr; give hydrocortisone 100mg IV &rarr; if recovers resume as per protocol at a slower rate. </p>
</li>
<li>If reaction is severe i.e. respiratory distress or angioedema or hypotension &rarr; stop infusion and do not restart &rarr; IV Benadryl 50mg + IV hydrocortisone + Oxygen + fluids &rarr; Bronchodilators if bronchospasm &rarr; consider IM adrenaline 0.5mg</li>
</ul>
<p><strong>A little about rituximab</strong>: Rituximab is extremely costly therefore in general we try to finish up the infusion. Please do not order for rituximab to be thrown away prior to checking with a Med Onco reg. <strong><em>Rituximab is only given if a tumour expresses CD 20+ (ie B Cell!!).</em></strong> If you see it written up for T cell, question it. Hold the chemo. Tell your consultant. If you catch this, you’ll have a super good lunch on us!!</p>
<p>24 hours after RCHOP because it is a myelosuppressive regime, remember that gCSF or PEGgCSF has to be given. Please check that midcycle methotrexate is not to be given with the RCHOP prior to giving gCSF.</p>
<h4 id="iv-methotrexate">IV METHOTREXATE<a class="headerlink" href="#iv-methotrexate" title="Permanent link">&para;</a></h4>
<ul>
<li>Preparation</li>
<li>Check FBC/Renal panel/Liver panel. </li>
<li>Ensure patient does not have any effusions as MTX can accumulate in them.</li>
<li>Hold off aspirin, omeprazole, Bactrim, penicillin and related antibiotics prior to giving MTX due to drug interactions.</li>
<li>Patients are hydrated with 3L of fluids (usually half strength NS) with 30 mmol of NaHCO3 in every 500mL of fluid. (cut down to 2L if patient has cardiac issues) </li>
<li>Monitoring</li>
<li>Check urine pH every shift. We aim urine pH &gt;7. Write a standing order for IV sodium bicarbonate 30 mmol bolus q8H to given if urine pH 7 or less. </li>
<li>Check I/O every shift. We aim for shift I/O &lt;500ml, daily I/O&lt;800mL.  Write a standing order for IV Lasix to be given if I &gt; O by 500ml per shift or 800 ml per day. These patients will need to be handed over to the on-call for the urine pH to be traced and shift I/O to be &lt; 500mL. </li>
<li>Logistics of Drug Delivery</li>
<li>IV MTX is usually given at 9am (ensure this is given before lunch by <strong>calling the hematology pharmacy the day before</strong> to ensure chemo prescription is received) and runs for 3 hours. </li>
<li>Ensure that methotrexate levels are ordered and checked at 24, 48 and 72 hours <strong>AFTER START</strong> of infusion ie 9 am days after chemo ends if chemo was given the day before. For the osteosarcoma patients, they will also have immediate end of infusion MTX levels measured this level can be ignored.<ul>
<li>At the same time MTX levels are checked, also order IV folinic acid 30mg q6 hour IV to start 24 hours after end of infusion. (order it and suspend it until it is due)</li>
<li>MTX blocking some of the effects of folic acid. A folate deficiency may cause side effects such as mouth sores, stomach problems such as nausea or abdominal pain, liver problems or problems with producing blood cells.</li>
</ul>
</li>
<li>We expect MTX levels to be 1 at 24 hours, 0.1 at 48 hours and &lt;0.05 at 72 hours. The dose of folinic acid is adjusted according to the MTX levels therefore <strong>call your registrars with the MTX levels</strong> so that they can adjust dose of folinic acid. </li>
<li>If MTX levels are between 0.05 - 0.1, send the patient home with PO folinic acid 15mg q6H for 6 doses. </li>
<li>GCSF can be given if MTX levels are &lt; 0.1. </li>
</ul>
<h4 id="cisplatin">Cisplatin<a class="headerlink" href="#cisplatin" title="Permanent link">&para;</a></h4>
<p>This is <strong>nephrotoxic</strong> and causes many <strong>electrolyte disturbance due to tubular damage</strong>. Ensure electrolytes and renal function are checked. Do ensure that the patient has IV fluids with electrolyte replacement ordered up. Refer to the protocols. </p>
<p><strong><em>Most of the lymphoma regimes are protocolled so look out for the chemo protocol. In ward 48/78 it is in a clear pocket in front of the file, in ward 72/77 it is in a separate file. Follow what it suggests especially with hydration and prophylactic Bactrim, acyclovir, antifungals, antibiotics etc. Don’t forget the delayed anti emetics. A puking patient is NOT a happy patient!</em></strong></p>
<h4 id="ifosfamide-eg-in-ice-ivac">Ifosfamide eg in ICE / IVAC<a class="headerlink" href="#ifosfamide-eg-in-ice-ivac" title="Permanent link">&para;</a></h4>
<p>Ensure urine dip stick done for blood every shift. Acrolein which is a metabolite of ifosfamide irritates the <strong>bladder lining causing haematuria</strong>. Ensure <strong>mesna</strong> which inactivates acrolein is being given.</p>
<h4 id="general-notes">General Notes<a class="headerlink" href="#general-notes" title="Permanent link">&para;</a></h4>
<p><strong>Lines</strong></p>
<p>Several of our chemo protocols require infusional chemo or patients have veins so delicate that a central line either PICC or Hickman line is required. </p>
<ul>
<li>If PICC is ordered, order a power PICC line, <strong>non tunneled</strong>, double lumen. </li>
<li>If Hickman order a <strong>non tunneled</strong> double lumen. </li>
</ul>
<h3 id="procedures">Procedures<a class="headerlink" href="#procedures" title="Permanent link">&para;</a></h3>
<ul>
<li>Accessing omaya reservoir</li>
<li>Bone marrow aspirate and trephine</li>
<li>Call Haematology Technician at 6321 4626 to arrange an appointment. Last time slot is 3pm. </li>
<li>
<p>The following items are needed (items can be obtained from W77/72/48)</p>
<ul>
<li>Dressing set; </li>
<li>Chlorhexidine </li>
<li>20ml syringes x 5</li>
<li>10ml syringe x 1 </li>
<li>Lignocaine 20ml (2 bottles) </li>
<li>Blue needle x 2</li>
<li>Green needle x 2 </li>
<li>Suture blade </li>
<li>Bone marrow needle</li>
<li>Formalin </li>
<li>Sterile drape x 2 </li>
<li>Sterile gown</li>
<li>Sterile gloves</li>
<li>Cap</li>
</ul>
</li>
<li>
<p>Blood culture</p>
</li>
<li>
<p>If the patient has a line, take 1 set from the line and 1 set from the peripheral</p>
</li>
<li>
<p>Lumbar puncture / Intra-thecal MTX</p>
</li>
<li>Ensure FBC / APTT / PT performed</li>
<li>Collect samples in the following order <ul>
<li>Flow cytometry (orange or light green tube) – Order General Lymphoma Screening Panel, indicate CSF </li>
<li>Cytology (dark green tube) – Order Histopathology, tick cytology</li>
<li>CSF FEME (red urine / specimen bottle)</li>
<li>At least 20 drops for the first two and 10 drops for the CSF FEME</li>
</ul>
</li>
</ul>
<p>First two bottles are for flow cyto**metry**. Last bottle for cytology</p>
<p><img alt="img" src="/Users/jzan/Dropbox/00-medicine/mkdoc-md-notes/docs/figures/clip_image002.png" /><img alt="img" src="/Users/jzan/Dropbox/00-medicine/mkdoc-md-notes/docs/figures/clip_image004.png" /><img alt="img" src="/Users/jzan/Dropbox/00-medicine/mkdoc-md-notes/docs/figures/clip_image005.jpg" /></p>
<h3 id="resources-and-numbers">Resources and Numbers<a class="headerlink" href="#resources-and-numbers" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Haem  pharm</th>
<th>4559</th>
<th>Cardiac  lab</th>
<th>5577</th>
<th>NCC</th>
<th>6436  8000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haem  tech</td>
<td>4626</td>
<td>BTS  MO</td>
<td>9186  4133</td>
<td>ATU  counter</td>
<td>6436  8100</td>
</tr>
<tr>
<td>Histo</td>
<td>4931</td>
<td>Jeslin</td>
<td>8442  8850</td>
<td>Morning  glory</td>
<td>6436  8160</td>
</tr>
<tr>
<td>Biochem</td>
<td>4653</td>
<td>Joanna</td>
<td>9238  8628</td>
<td>Jasmine</td>
<td>6436  8134</td>
</tr>
<tr>
<td>Haem  lab</td>
<td>4628</td>
<td>Nuclear  med</td>
<td>5357</td>
<td>Chai  Pan</td>
<td>9021  8733</td>
</tr>
</tbody>
</table>
<p><a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a> – good for chemotherapy protocols, supportive measures</p>
<p><a href="http://www.macmillan.org.uk">www.macmillan.org.uk</a> – similar to BC cancer agency but from the UK</p>
<p><a href="http://www.nccn.org">www.nccn.org</a> – good for guidelines on cancer management by cancer types but will need you to register to login, also has some supportive care</p>
<p>Take home message – <strong>CALL FOR HELP</strong> if you are not sure. </p>
                
                  
                    

<hr>
<div class="md-source-date">
  <small>
    
      Last update: June 25, 2020
    
  </small>
</div>
                  
                
              
              
                


              
            </article>
          </div>
        </div>
      </main>
      
        
<footer class="md-footer">
  
    <div class="md-footer-nav">
      <nav class="md-footer-nav__inner md-grid" aria-label="Footer">
        
          <a href="../hematology/" title="Hematology" class="md-footer-nav__link md-footer-nav__link--prev" rel="prev">
            <div class="md-footer-nav__button md-icon">
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12z"/></svg>
            </div>
            <div class="md-footer-nav__title">
              <div class="md-ellipsis">
                <span class="md-footer-nav__direction">
                  Previous
                </span>
                Hematology
              </div>
            </div>
          </a>
        
        
          <a href="../msk/" title="Msk" class="md-footer-nav__link md-footer-nav__link--next" rel="next">
            <div class="md-footer-nav__title">
              <div class="md-ellipsis">
                <span class="md-footer-nav__direction">
                  Next
                </span>
                Msk
              </div>
            </div>
            <div class="md-footer-nav__button md-icon">
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M4 11v2h12l-5.5 5.5 1.42 1.42L19.84 12l-7.92-7.92L10.5 5.5 16 11H4z"/></svg>
            </div>
          </a>
        
      </nav>
    </div>
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-footer-copyright">
        
          <div class="md-footer-copyright__highlight">
            Copyright &copy; 2020 Jingzhi An
          </div>
        
        Made with
        <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
          Material for MkDocs
        </a>
      </div>
      
  <div class="md-footer-social">
    
      
      
        
        
      
      <a href="https://github.com/jingzhian" target="_blank" rel="noopener" title="github.com" class="md-footer-social__link">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 480 512"><path d="M186.1 328.7c0 20.9-10.9 55.1-36.7 55.1s-36.7-34.2-36.7-55.1 10.9-55.1 36.7-55.1 36.7 34.2 36.7 55.1zM480 278.2c0 31.9-3.2 65.7-17.5 95-37.9 76.6-142.1 74.8-216.7 74.8-75.8 0-186.2 2.7-225.6-74.8-14.6-29-20.2-63.1-20.2-95 0-41.9 13.9-81.5 41.5-113.6-5.2-15.8-7.7-32.4-7.7-48.8 0-21.5 4.9-32.3 14.6-51.8 45.3 0 74.3 9 108.8 36 29-6.9 58.8-10 88.7-10 27 0 54.2 2.9 80.4 9.2 34-26.7 63-35.2 107.8-35.2 9.8 19.5 14.6 30.3 14.6 51.8 0 16.4-2.6 32.7-7.7 48.2 27.5 32.4 39 72.3 39 114.2zm-64.3 50.5c0-43.9-26.7-82.6-73.5-82.6-18.9 0-37 3.4-56 6-14.9 2.3-29.8 3.2-45.1 3.2-15.2 0-30.1-.9-45.1-3.2-18.7-2.6-37-6-56-6-46.8 0-73.5 38.7-73.5 82.6 0 87.8 80.4 101.3 150.4 101.3h48.2c70.3 0 150.6-13.4 150.6-101.3zm-82.6-55.1c-25.8 0-36.7 34.2-36.7 55.1s10.9 55.1 36.7 55.1 36.7-34.2 36.7-55.1-10.9-55.1-36.7-55.1z"/></svg>
      </a>
    
      
      
        
        
      
      <a href="https://twitter.com/drdrjzan" target="_blank" rel="noopener" title="twitter.com" class="md-footer-social__link">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path d="M459.37 151.716c.325 4.548.325 9.097.325 13.645 0 138.72-105.583 298.558-298.558 298.558-59.452 0-114.68-17.219-161.137-47.106 8.447.974 16.568 1.299 25.34 1.299 49.055 0 94.213-16.568 130.274-44.832-46.132-.975-84.792-31.188-98.112-72.772 6.498.974 12.995 1.624 19.818 1.624 9.421 0 18.843-1.3 27.614-3.573-48.081-9.747-84.143-51.98-84.143-102.985v-1.299c13.969 7.797 30.214 12.67 47.431 13.319-28.264-18.843-46.781-51.005-46.781-87.391 0-19.492 5.197-37.36 14.294-52.954 51.655 63.675 129.3 105.258 216.365 109.807-1.624-7.797-2.599-15.918-2.599-24.04 0-57.828 46.782-104.934 104.934-104.934 30.213 0 57.502 12.67 76.67 33.137 23.715-4.548 46.456-13.32 66.599-25.34-7.798 24.366-24.366 44.833-46.132 57.827 21.117-2.273 41.584-8.122 60.426-16.243-14.292 20.791-32.161 39.308-52.628 54.253z"/></svg>
      </a>
    
      
      
        
        
      
      <a href="https://linkedin.com/in/jingzhi-an-281a9315" target="_blank" rel="noopener" title="linkedin.com" class="md-footer-social__link">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"/></svg>
      </a>
    
  </div>

    </div>
  </div>
</footer>
      
    </div>
    
      <script src="../assets/javascripts/vendor.d710d30a.min.js"></script>
      <script src="../assets/javascripts/bundle.4a5ba8d6.min.js"></script><script id="__lang" type="application/json">{"clipboard.copy": "Copy to clipboard", "clipboard.copied": "Copied to clipboard", "search.config.lang": "en", "search.config.pipeline": "trimmer, stopWordFilter", "search.config.separator": "[\\s\\-]+", "search.result.placeholder": "Type to start searching", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents"}</script>
      
      <script>
        app = initialize({
          base: "..",
          features: ["tabs"],
          search: Object.assign({
            worker: "../assets/javascripts/worker/search.9b3611bd.min.js"
          }, typeof search !== "undefined" && search)
        })
      </script>
      
        <script src="../javascripts/extra.js"></script>
      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
      
    
  </body>
</html>